Fusion Pharmaceuticals Inc. (FUSN) Reports Q1 Earnings; Provides Clinical Program Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stocks set for lower open as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates
May 11, 2023 7:15 AM EDTFPI-2265 (Ac-PSMA I&T) program enrolling patients and on track for Q1 2024 update Â
Preliminary Phase 1 data for FPI-1434 expected to be reported at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
Clinical progress across TAT pipeline continues; first patient dosed in Phase 1 study of FPI-2059; FPI-2068, a bispecific TAT jointly developed with AZ, IND has cleared
FPI-1966 program to be discontinued due to portfolio prioritization decision
$20.0 million... More
